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TREATMENT OF KNEE OA WITH ACETAMINOPHEN
(3-4gr/day) DURING 12 MONTHS: A NATURALISTIC
PROSPECTIVE STUDY
C. Fernández-López1, N. Oreiro1, M. Freire1,
M. Bonome-González2, S. Reboiro1, J. Fernández-Sueiro1,
F. Galdo1, F.J. Blanco1
1Rheumatology Division. Clinical Research Unit, CH
Universitario Juan Canalejo, Coruña, Spain; 2Centro Salud de
Matogrande, Coruña, Spain
Purpose: Osteoarthritis (OA) is the more common rheumatic
diseases. Acetominophen (3-4 gr/day), is a therapeutic alterna-
tive to treat symptomatic knee OA. Effectiveness and security
data from long term studies using acetominophen in naturalistic
conditions is scarce.
To study the security and effectiveness data of acetominophen
at doses of 4gr/day in real conditions during 6 and 12 months.
Methods: This observational, naturalistic, open and prospective
clinical trial was conducted in a Spanish rheumatology clinic. All
included patients were treated with acetaminophen at doses of
4gr/day during the ﬁrst 6 months, and then doses were regulated
according symptoms of patients. Visits were performed at 3, 6,
9 and 12 months. Pain EVA and WOMAC were employed to
quantify effectiveness. Data from security were also recorded.
Results: 219 patients were included: 87.4% females, age
65.5±8.76 years and BMI 32.9±5.3. Duration of knee OA was
49.9±63.4 years. Baseline WOMAC values were: Pain = 6.9±2.8,
Stiffness = 3±1.7, Function = 25±11.7. Baseline pain-EVA was
46.1±21.4. Knee OA was bilateral in 93.0% of patients. 178
patients complete the protocol at 6 months and 139 patients
at 12 months. Pain-EVA [media (95% IC)] at 6 months was
37.1 (33.9-41.6) and 38.1 (33.9-42.2) at 12 months (p=0.01 and
p<0.001 respectively). WOMAC values at 6 months were [me-
dia (95% IC)]: Pain = 6.6 (6.1-7.2), Stiffness = 2.7 (2.5-3.0),
Function = 24.0 (22.2-25.8). WOMAC values at 12 months were:
Pain = 6.4 (5.8-6.9), Stiffness = 2.8 (2.5-3.1), Function = 24.9
(23.0-26.9). At 6 and 12 months 42.9% and 40.3% of patients
were responders according OARSI criteria. Two hundred forty
adverse events were reported, 76% of them were low level ad-
verse events. The most frequent adverse event was infections of
respiratory tract. Eight adverse events were classiﬁed as severe,
2 of them were hepatotoxic adverse events and acetaminophen
was dropped.
Conclusions: In naturalistic conditions, acetaminophen at doses
of 3-4gr/day reduces pain in patients with knee OA and it is a
secure drug.
This clinical trail was supported by Bristol-Mayers-Squibb.
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INHIBITION BY HYALURONAN OF COLLAGENASE
PRODUCTION THROUGH NUCLEAR FACTOR-κB
DOWN-REGULATION IN OSTEOARTHRITIS
CHONDROCYTES STIMULATED WITH COOH-TERMINAL
HEPARIN-BINDING FIBRONECTIN FRAGMENT
T. Yasuda
Department of Sports Medicine, Tenri University, Tenri, Japan
Purpose: Increased ﬁbronectin fragments are thought to be
involved in cartilage destruction in osteoarthritis (OA) through
their catabolic activities. At present, whether ﬁbronectin frag-
ments can activate nuclear factor (NF)-κB in OA chondrocytes
remains unknown. In addition, hyaluronan (HA) effect on ﬁ-
bronectin fragment-activated intracellular pathways remains to
be clariﬁed. This study was aimed to examine the inhibitory ef-
fect of HA on collagenase production through NF-κB activation by
COOH-terminal heparin-binding ﬁbronectin fragment (HBFN-f) in
OA chondrocytes.
Methods: OA cartilage was harvested from knee joint at re-
placement surgery, and chondrocytes were kept in monolayer
or cartilage explant cultures in the presence of HBFN-f. Se-
creted levels of matrix metalloproteinase (MMP)-1 and MMP-13
in conditioned media were determined by immunoblot analysis.
NF-κB activation and nuclear translocation were evaluated by
immunoblot analysis. Cultures were pretreated with 2700 kDa
HA to evaluate the inhibitory effect on HBFN-f action.
Results: HBFN-f enhanced MMP-1 and MMP-13 in OA carti-
lage explant culture. The speciﬁc NF-κB inhibitor, BAY11-7085
conﬁrmed the requirement of NF-κB for collagenase induction
by HBFN-f. HBFN-f activated NF-κB, leading to NF-κB nuclear
translocation in OA chondrocyte monolayer culture. Pretreatment
with HA resulted in signiﬁcant suppression of NF-κB phospho-
rylation and nuclear translocation by HBFN-f. HA also inhibited
HBFN-f-stimulated production of MMP-1 and MMP-13 in OA
cartilage explant culture.
Conclusions: The present study clearly demonstrated that
HBFN-f activated NF-κB in OA chondrocytes, while high molec-
ular weight HA inhibited such activation. When HA is therapeuti-
cally introduced into OA joints, therefore, HA could suppress the
catabolic actions of ﬁbronectin fragments like HBFN-f as a potent
NF-κB inhibitor.
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APPLYING THE HERBAL THERAPY ROSE-HIP IN
OSTEOARTHRITIS PATIENTS: A SYSTEMATIC REVIEW
AND A META-ANALYSIS
R. Christensen Sr.1, H. Lund1, E. Bartels2, A. Astrup3,
H. Bliddal1
1The Parker Institute, Frederiksberg, Denmark; 2Copenhagen
University Library, Copenhagen, Denmark; 3Department of
Human Nutrition, Copenhagen, Denmark
Purpose: To give a systematic review, with a quality assessment
and meta-analysis of clinical trials, of rose-hip supplement (a
herbal remedy) for knee and/or hip OA symptoms.
Methods: The bibliographical databases PubMed, EMBASE,
CINAHL, Scopus, Sciﬁnder, Web of Science, and PEDro, as well
as The Cochrane Controlled Trials Register and Scirus, were
searched for randomised controlled trials (RCTs) of subjects with
(knee or hip) osteoarthritis (OA) - using the terms: osteoarthritis,
osteoarthrosis, degenerative arthritis - combined with rose-hip,
rosa canina, ros* AND herb*, “hyben vital”, “Litozin”. We also did
a manual search of reference lists in review articles, manuscripts,
and supplements from rheumatology and OA journals. Inclusion,
quality scoring, and data abstraction were performed systemati-
cally by 2 independent reviewers. Outcome data were extracted
for pain and disability. For each included trial, the number of re-
sponders was estimated, and standardised mean difference was
calculated as the Effect Size (ES) for pain, and disability based
on the corresponding relevant z-statistics. We calculated Odds
Ratio’s (OR) for the number of patients responding to treatment,
supported by the Number Needed to Treat (NNT) for clinical
response. For the meta-analyses we used a (SAS) mixed lin-
ear model, but applied a restricted maximum likelihood (REML)
method.
Results: A total of four RCTs, including two with a cross-over de-
sign, were eligible for meta-analysis. This included 360 patients
with symptomatic knee and/or hip OA; 229 of these patients were
allocated to rose-hip supplement treatment. The studies had an
arithmetic mean quality score of 3.90 (78.1% max). All three
outcomes - pain, disability, and number of responders - seemed
homogenous (P>0.17), supported by the I-square: 39.5%, <0%,
and 37.5%, respectively (indicating consistency). Based on the
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REML - ﬁxed-effects - model, rose-hip resulted in a statistically
signiﬁcant small reduction in pain (ES [95% CI]: -0.21 [-0.35 to
-0.07]; p=0.004), disability (-0.22 [-0.36 to -0.07]; p=0.003), with
more patients likely to respond to treatment when compared to
the untreated controls (OR: 3.04 [2.04 to 4.52]; p<0.0001). This
OR - adjusted for the weighted control event rate - corresponded
to a NNT of 4 (3 to 6) patients.
Conclusions:Based on the available evidence, we conclude that
a supplement of rose-hip might result in some symptomatic relief
in many osteoarthritis patients. The clinical efﬁcacy was small
and in the same range as that of paracetamol (acetaminophen).
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PREDICTIVE FACTORS OF RESPONSE IN A
RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED EVALUATION OF THE EFFICACY OF A
SINGLE DOSE OF 6 ML OF HYLAN G-F 20 IN PATIENTS
WITH SYMPTOMATIC KNEE OSTEOARTHRITIS
F. Bailleul1, X. Chevalier2, K. Pavelka3
1Genzyme Biosurgery, Medical Affairs, France; 2Hôpital Henri
Mondor, Créteil, France; 3Institute of Rheumatology, Prague,
Czech Republic
Purpose: To compare the efﬁcacy of 1x6mL intra-articular (IA)
administration of hylan G-F 20 (Synvisc-One™) against placebo
in different sub-populations of patients with symptomatic OA of
the knee.
Methods: Prospective, multicenter, randomized, double-blind
(patient, independent clinical observer) study comparing 1 IA
injection of 6mL of hylan G-F 20 (H) or saline (S). Patients must
have documented diagnosis of OA of the target knee made at
least 3 months prior to screening. Patients with symptomatic OA
of the contralateral knee or either hip not responsive to parac-
etamol and requiring other therapy were excluded. The primary
efﬁcacy analysis used WOMAC A Likert pain and was performed
on the ITT population, based on a repeated-measures model
over the 26 weeks of the follow up.
Results: 253 patients were randomized (H N=124, S N=129).
Mean age 63 years (42-84), BMI 29.4 (19.5-52.4), 71% fe-
male, primary knee OA Kellgren Lawrence (KL) grade 2 (45%)
or 3 (55%). Overall, patients in the H group experienced a
mean change from baseline in their WOMAC A pain score over
26 weeks which was statistically signiﬁcantly different from the
change reported in the S group ( = -0.15, p = 0.047).
The OA status in the contralateral knee and hips made a differ-
ence with hylan G-F 20 being more effective over 26 weeks in
the patients without other joints involvement (N = 105,  = -0.31)
as compared to patients with symptomatic OA in lower limbs (N
= 148,  = -0.04, treatment by OA interaction p = 0.03).
Similarly, hylan G-F 20 tends to have a greater effect over 26
weeks in patients with KL grade 0-II tibio-femoral OA (N = 114,
 = -0.22) as compared with grade III-IV (N = 139  = -0.08,
interaction p = 0.17).
In the subgroup of patients with severe baseline WOMAC A1
pain, hylan G-F 20 demonstrated a greater symptomatic effect at
week 26 (N = 90,  = -0.28) than in the subgroup with moderate
baseline pain (N = 163,  = -0.13), but there was no statistical
difference over the 26 weeks of the study.
Conclusions: In this study, the positive predictive factors of
symptomatic response after IA injection of a single 6 ml dose of
hylan G-F 20 in patients with knee OA were high level of baseline
pain, early grade OA and no concurrent lower limb OA.
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THE ROLE OF MSM IN KNEE OSTEOARTHRITIS:
A DOUBLE BLIND, RANDOMIZED, PROSPECTIVE STUDY
R. Debi, G. Fichman, Y. Bar Ziv, R. Kardosh, E. Debbi,
N. Halperin, G. Agar
Asaf Harofe Medical Center, Tel Aviv, Israel
Purpose: Osteoarthritis (OA) is among the most common causes
of disability in the elderly. Since the recent publications illustrat-
ing the lethal adverse affects of cox-2 selective anti-inﬂamatory
drugs, there has emerged a need for safe long term treatment in
OA. As a result, patients have begun using dietary supplements
sold OTC. These include glucoseamine, chondroitine sulfate and
methylsulfonylmethane (MSM). MSM is a natural substance pro-
duced in our body that has analgesic and anti-inﬂammatory
properties. There is lack of research on the efﬁcacy of MSM in
treating knee OA. The aim of the study was to determine the
efﬁcacy of MSM in treating knee OA patients.
Methods: This study is a prospective, randomized, double-
blinded, controlled study. 60 men and women, 45-90 (68 ±7.3)
years of age with knee OA graded 1-4 (3 ±1) according to
Kellgren & Lawrence, were enrolled in the study and randomly
assigned into 2 groups: One receiving MSM in doses of 1.125
milligrams 3 times daily, and the other receiving a placebo. Pa-
tients were assessed at baseline, 6, and 12 weeks. During their
appointments, the patients were asked to ﬁll out questioners
on their pain and physical function: SF-36, WOMAC, KFS, and
KSS. The patients physical function was also assessed using
Aggregated Locomotor Function (ALF).
Results: There were signiﬁcant improvements in pain, stiffness,
and physical function in the experimental group according to
both the WOMAC questioner (p-value=0.009) and the SF36
questioner (p-value=0.031). No signiﬁcant differences between
the groups were found using the KSS and KFS questioners. A
seven second improvement in the total time measured (ALF) was
also found in the study group, while no such improvement was
seen in the placebo group (p-value=0.009). No adverse effects
were recorded.
Conclusions: The ﬁndings demonstrate that methylsulfonyl-
methane (MSM) is effective and signiﬁcantly improve function
and reduce pain in knee OA patients.
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COMPARATIVE EVALUATION OF THE EFFICACY SAFETY
AND TOLERABILITY OF LORNOXICAM AND
DICLOFENAC IN INDIAN PATIENTS WITH
OSTEOARTHRITIS
V.P. Baliga1, A. Goregaonkar2, K.J. Mathiazhagan3,
R.R. Shah4, P. Taneja5, A. Sharma1
1Glenmark Pharmaceuticals Ltd, Mumbai, India; 2LTMM College
aand General Hospital, Mumbai, India; 3Govt Kilpauk Medical
College, Chennai, India; 4Khaja Banda Nawaz Institute of
Medical Sciences, Gulbarga, India; 5RGS Healthcare Pvt. Ltd.,
Mohali, India
Purpose: Reports of cardiovascular adverse events associated
with the use of GI-COX-2 speciﬁc inhibitors for chronic therapy
of osteoarthritis have prompted the quest for a safer NSAID. The
present study was undertaken to compare the efﬁcacy, safety
and tolerability of oral lornoxicam and diclofenac in adult Indian
patients with osteoarthritis.
Methods: This prospective, double-blind, randomized, compar-
ative, multicentric study was undertaken in 260 adult Indian
patients, in 5 centers across the country. The study protocol
was approved by respective Institutional review boards. Written
informed consent was obtained from each patient prior to un-
